drugset / Trial / NCT00311883

Hydroxychloroquine in Cystic Fibrosis

NCT00311883

Phase 1 Completed 20 enrolled Vanderbilt University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.

Timeline

Start
2006-03
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications